Karen Wilde knows from her own perspective how important it is to that Myeloma Australia receives financial support and that's why she's thrilled that the racing industry will again be to the fore ...
When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
Researchers discover that bone marrow cancer cells diversify drastically when exiting the bone marrow, which also affects the ...
Upregulation of cytokines and chemokines is a frequent finding in multiple myeloma (MM ... contribute to the development of bone disease in MM by supporting tumor growth and regulating osteoclast ...
2d
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Furthermore, the anti-DKK-1-treated mice showed reduced tumor burden. [141] Bone disease is a hallmark of multiple myeloma (MM), associated with bone pain, pathological fractures requiring surgery ...
When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response ...
Bone disease is a hallmark of multiple myeloma (MM), associated with bone pain, pathological fractures requiring surgery and/or radiation to bone, spinal cord compression and hypercalcemia.
Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA has granted orphan drug designation (ODD) to ...
Black Americans have double the risk of developing multiple myeloma compared to white Americans and are diagnosed at younger ages.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback